Oxavar 10
Oxandrolone is a mild, low androgen 17-alpha alkylated anabolic steroid with very low toxicity. It promotes protein anabolism and rarely causes any adverse reactions, Oxandrolone is primarily used to promote strength, muscle hardness and quality physique improvement. In the International Journal of Obesity, (1995; 19: 614-624), it was shown that Oxandralone enhanced bodyfat reduction significantly in both the abdominal and visceral stores. Oxandrolone will not aromatize, and therefore the anabolic effect of this compound can actually promote linear growth. Oxandrolone is also prescribed for the treatment of osteoporosis.
OXAVAR 10
Chemical: Oxandrolone
CAS Name: (4aS,4bS,6aS,7S,9aS,9bR,11aS)-Tetradecahydro-7-hydroxy-4a,6a,7trimethylcyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one
Additional Names: 17-hydroxy-17-methyl-2-oxa-5-androstan-3-one; dodecahydro-3hydroxy-6-(hydroxymethyl)-3,3a,6-trimethyl-1H-benz[e]indene-7-acetic acid -lactone
Molecular Formula: C19H30O3
Molecular Weight: 306.44.
Percent Composition: C 74.47%, H 9.87%, O 15.66%
Prescription Medicine
OXAVAR 10
Each uncoated tablet contains : Oxandrolone 10 mg
DESCRIPTION:
Oxavar 10 tablets contain 10 mg of the anabolic steroid Oxandrolone.
CLINICAL PHARMACOLOGY:
Anabolic steroids, which are synthetic derivatives of testosterone, have actions similar to the endogenous male sex hormone. The anabolic action may not be completely dissociated from the androgenic affects. They suppress gonadotropic function of the pituitary and may also have a direct effect on the testes. Endogenous testosterone release might be suppressed due to the inhibition of the luteinizing hormone (LH). And the inhibition of FSH may also affect spermatogenesis.
INDICATION AND USAGE:
Oxavar 10 is used as an alternate therapy in patients who find it difficult to gain weight due to several conditions such as chronic infections, trauma and after surgery. It may also be given as a relief for bone pain due to osteoporosis.
CONTRAINDICATION:
Hypercalcemia.
- Carcinoma of the breast in females with hypercalcemia
- Pregnancy Because of possible masculinization of the fetus.
- Nephrosis
- Known or suspected carcinoma of the prostate or the male breast
WARNINGS:
Patients receiving androgenic anabolic steroid therapy have been reported to have a condition known as Peliosis Hepatis, where the liver and/or the splenic tissue are replaced with blood filled cysts. These cysts are associated with liver failure and are not often recognized until life threatening.
PRECAUTIONS:
Virilization marked by deepening of the voice, hirsutism, acne, etc. should be observed in women. Immediate discontinuation should be done upon onset of mild virilization to prevent irreversible virilization. Suppression of clotting factors II, V, VII, X may occur and may increase prothrombin time, so patients should report any use of warfarin and any bleeding.
LABORATORY TESTS:
Periodical liver function tests should be obtained due to hepatoxicity with 17-alpha-alkylated androgens. Periodical hemoglobin and hematocrit for patients with polycythemia receiving high-dose anabolics. Periodical serum lipids and high-density lipoprotein cholesterol due to increase in low-density lipoprotein reported on use of androgenic anabolic steroid. Periodic examination of bone age by x-ray during treatment in children to determine bone maturation rate and effect on epiphysial centers. Frequent determination of urine and serum calcium levels in women with disseminated breast carcinoma during therapy.
DRUG INTERACTIONS:
- Oral hypoglycemic agents: Oxavar 10 may inhibit the metabolism of oral hypoglycemic agents.
- Adrenal steroids or ACTH: May exacerbate edema in patients on adrenal cortical steroids or ACTH
Anticoagulants: Patients should be closely monitored when they are on concomitant anticoagulant and Oxavar 10 therapy.
PREGNANCY, LACTATION AND PEDIATRIC USE :
Pregnancy Category X
It is not known whether anabolics are excreted in milk, but due to the harm the drug may give infants, a decision should be made by t he nursing mother whether to continue the drug or not. Use in children should be closely monitored by x-ray due to the possibility of accelerating epiphysial maturation. Great caution should be observed during therapy.
ADVERSE REACTIONS :
Hepatic: Peliosis hepatis, Cholestatic jaundice, hepatic necrosis, hepatocellular neoplasms; May affect liver function tests, bromsulfophthalein (BSP), serum bilirubin, aspartate aminotransferase (AST, SGOT) & alkaline phosphatase. CNS: Changes in libido, habituation, excitation, insomnia, and depression. Hematologic: Bleeding on concomitant anticoagulant therapy. Breast: Gynecomastia. Larynx: Deepening of the voice in females.
Hair: Hirsutism and male pattern baldness in females. Skin: Acne (especially in females and prepubertal males). Skeletal: Premature closure of epiphyses in children In males: Prepubertal: Increased frequency of erections Postpubertal: testicular atrophy, chronic priapism, oligospermia, impotence, epididymitis, and bladder irritability. In females: virilization such as clitoral enlargement and menstrual irregularities.
OVERDOSAGE :
No symptoms or signs associated with overdosage with Oxavar 10 have been reported.
DOSAGE AND ADMINISTRATION:
Adults: One 10-mg tablet once daily. However, the response may vary per person, and a daily dosage of as little as 2.5 mg or as much as 20 mg may be required to achieve the desired response. Children: For children the total daily dosage of Oxandrolone is < = 0.1 mg per kilogram body weight. This may be repeated intermittently as indicated.
PRESENTATION:
10 mg Tablets packed in 5 blister packs of 10 each.
STORAGE:
Store in a cool dry place (30 C ± 2 C). Protect from light.
Prescription Medicine
Oxavar 10
Each uncoated tablet contains : Oxandrolone 10 mg